Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-504"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"sk"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-504"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-5052
lpv:speaker	lp:Miroslav Mikolášik2
lpv:spokenAs	substitute; DROI (2009-07-16--2012-01-18)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; Delegation for relations with Belarus (2009-09-16--2013-09-25)3 member; REGI (2009-07-16--2012-01-18)3 substitute; ENVI (2009-07-16--2012-01-18)3 member; Delegation for relations with the Korean Peninsula (2009-09-16--2014-06-30)3 unknown; Kresťanskodemokratické hnutie (2009-07-14--2014-06-30)3 member; EPP (2009-07-14--2014-06-30)3
lpv:translated text	"The aim of pharmacovigilance is to ensure that patients and hence, the relevant authorities, report everything, and not just serious adverse effects, to the EudraVigilance database. All information on the adverse effects of medicines will thus be concentrated for the first time in one place, representing a valuable research instrument. Measures can then be adopted on the basis of this, such as changes to methods of prescribing, better provision of information on the use of medicines and even withdrawals of medicines from the market. I support proposals aimed at motivating informed patients, who will have available all the relevant information on a medicine in the accompanying leaflet. The system should not only inform patients but also motivate them to report any adverse effects. Manufacturers must not conceal any adverse side effects of a product, as happened in the case of hormonal contraceptives, for example. Both of Mrs McAvan’s reports represent progress and will be of benefit to all patients by providing access to safer medicines in the EU and a legal framework for the competent authorities."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph